Madrigal Pharmaceuticals, Inc. (MDGL) Dividend History

Madrigal Pharmaceuticals, Inc. (MDGL) is a biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases. It specializes in using innovative research to create targeted treatments, with a particular emphasis on conditions such as non-alcoholic steatohepatitis (NASH) and related liver diseases.

200 Barr Harbor Drive, Suite 400, West Conshohocken, PA, 19428
Phone: 404-380-9263
Website: http://www.madrigalpharma.com

Dividend History

Madrigal Pharmaceuticals, Inc. currently does not pay dividends

Company News

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra, demonstrating significant improvements in liver stiffness, liver fat, fibrosis biomarkers, liver volume, and risk scores for clinically significant portal hypertension.

GlobeNewswire Inc.
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Madrigal Pharmaceuticals, a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH), will release its Q1 2025 financial results and host a webcast on May 1, 2025.

GlobeNewswire Inc.
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

Madrigal Pharmaceuticals reported positive two-year data for its drug Rezdiffra in treating compensated MASH cirrhosis, showing significant reductions in liver stiffness. The company also reported better-than-expected Q4 financial results.

Benzinga
Why Madrigal Pharmaceuticals Stock Is Soaring Today

Madrigal Pharmaceuticals reported strong Q4 2024 results, with revenue and earnings beating analyst estimates. The company also announced positive new two-year data from a phase 3 study of its MASH drug Rezdiffra, adding to the optimism about the drug's potential.

The Motley Fool
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Madrigal Pharmaceuticals, a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), will release its fourth-quarter and full-year 2024 financial results on February 26, 2025, and host a live webcast to review the results.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:01:14 UTC